HUMAN METABOLISM AND DISPOSITION OF DAPRODUSTAT: A PROLYL HYDROXYLASE INHIBITOR TO TREAT ANEMIA IN CHRONIC KIDNEY DISEASE (CKD).

被引：0
|
作者：
Chen, L. [1 ]
Xia, F. [1 ]
Chen, C. [1 ]
Felgate, C. [2 ]
Pereira, A. [3 ]
Pirhalla, J. [1 ]
Miao, X. [1 ]
Young, G. [3 ]
Beaumont, C. [3 ]
Tai, G. [1 ]
机构：
[1] GlaxoSmithKline, Collegeville, PA USA
[2] GMX, Ware, Herts, England
[3] GlaxoSmithKline, Ware, Herts, England
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2021年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIII-035
引用
收藏
页码：S54 / S54
页数：1
相关论文
共 50 条
  • [11] HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease
    Wyatt, Christina M.
    Drueke, Tilman B.
    [J]. KIDNEY INTERNATIONAL, 2016, 90 (05) : 923 - 925
  • [12] Oral Daprodustat Treats Anemia in Chronic Kidney Disease
    Slomski, Anita
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (08): : 710 - 710
  • [13] VADADUSTAT Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor Treatment of anemia secondary to chronic kidney disease
    Cole, P.
    [J]. DRUGS OF THE FUTURE, 2016, 41 (10) : 601 - 606
  • [14] Daprodustat, a Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor, Improves Hematological Insufficiency without Progression of Myelodysplastic Syndrome with Chronic Kidney Disease
    Hara, Ryujiro
    Kitahara, Toshihiko
    Numata, Hiroki
    Watanabe, Shigeki
    Kikkawa, Eri
    Onizuka, Makoto
    Kawada, Hiroshi
    [J]. BLOOD, 2023, 142
  • [15] Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease
    Uchida, Lisa
    Tanaka, Tetsuhiro
    Saito, Hisako
    Sugahara, Mai
    Wakashima, Takeshi
    Fukui, Kenji
    Nangaku, Masaomi
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2020, 318 (02) : F388 - F401
  • [16] Investigation of the human metabolism and disposition of the prolyl hydrolase inhibitor daprodustat using IV microtracer with Entero-Test bile string
    Tai, Guoying
    Xia, Fangming
    Chen, Cathy
    Pereira, Adrian
    Pirhalla, Jill
    Miao, Xiusheng
    Young, Graeme
    Beaumont, Claire
    Chen, Liangfu
    [J]. PHARMACOLOGY RESEARCH & PERSPECTIVES, 2023, 11 (06):
  • [17] Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease
    del Balzo, Ughetta
    Signore, Pierre E.
    Walkinshaw, Gail
    Seeley, Todd W.
    Brenner, Mitchell C.
    Wang, Qingjian
    Guo, Guangjie
    Arend, Michael P.
    Flippin, Lee A.
    Chow, F. Aisha
    Gervasi, David C.
    Kjaergaard, Christian H.
    Langsetmo, Ingrid
    Guenzler, Volkmar
    Liu, David Y.
    Klaus, Steve J.
    Lin, Al
    Neff, Thomas B.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2020, 374 (02): : 342 - 353
  • [18] Use of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, in chronic kidney disease-associated anemia in cats
    Charles, Samuel
    Suessenberger, Ricarda
    Settje, Terry
    Langston, Catherine
    Lainesse, Chantal
    [J]. JOURNAL OF VETERINARY INTERNAL MEDICINE, 2024, 38 (01) : 197 - 204
  • [19] Inhibition of HIF prolyl-hydroxylase domain to correct anemia in patients with chronic kidney disease
    Wyatt, Christina M.
    Drueke, Tilman B.
    [J]. KIDNEY INTERNATIONAL, 2020, 97 (04) : 639 - 642
  • [20] Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease
    Sugahara, Mai
    Tanaka, Tetsuhiro
    Nangaku, Masaomi
    [J]. KIDNEY INTERNATIONAL, 2017, 92 (02)
12345